SLC5A9 (inhibition, Figure S5-2) was the most affected starting node at 2 h of treatment, which suggests that down-regulation of SLC5A9 is a potential MIE in an AOP for fibrosis, cholestasis or liver cancer. The gene discussed is SLC5A9; the disease is liver cancer.